The Australian Government is now in caretaker period. During this time, updates on this website will be published in accordance with the Guidance on Caretaker Conventions, until after the election.
2709 results found
There is a long running interest in the idea of machine-organism hybrids, although the integration of electronic and biological systems remains underdeveloped. Professor Kirill Alexandrov and his collaborators received Human Frontier Science Program (HFSP) funding to explore the 'undoable'. Multidisciplinary teams are a must and spur new creative projects.
In the final days of Professor Anne Kelso’s term at NHMRC, we are reflecting on changes that have taken place at the agency and in the wider sector while she has served as CEO. During an interview with Cate Swannell for the MJA Podcast on December 5 2022, Professor Kelso discussed some of the most significant experiences of her tenure, including the introduction of an initiative to address gender disparities in the Investigator Grant scheme.
High-quality national clinical trials and cohort studies aiming to improve the health and wellbeing of all Australians will receive over $77 million in funding under the National Health and Medical Research Council’s (NHMRC) Clinical Trials and Cohort Studies grant scheme.
Professor Alta Schutte, SHARP Professor and Principal Theme Lead of Cardiac, Vascular and Metabolic Medicine at the University of New South Wales and The George Institute for Global Health, focuses on implementing effective scalable interventions for global blood pressure control. Appointed Co-Chair of the National Hypertension Taskforce in 2022, she was recognised in 2023 as the Leading Researcher in Vascular Medicine by The Australian. Notably, she received the 2022 Harriet Dustan Award from the American Heart Association and the 2023 Peter Sleight Excellence award from the World Hypertension League. Her impactful work extends to improving cardiovascular health in Australia and beyond.
Professor Sharon Lewin is the Director of the Peter Doherty Institute for Infection and Immunity at the University of Melbourne. Her research has focused on strategies to achieve an HIV cure, enhancing clinical outcomes for people living with HIV and hepatitis B and the identification of novel treatments for COVID-19. She is internationally known for her development of laboratory models to study HIV latency and for leading innovative early phase clinical trials aimed at reversing HIV latency. Professor Lewin has received Melburnian of the Year (2014), the Peter Wills Medal from Research Australia (2015), Officer of the Order of Australia (2019), and Medal for Outstanding Female Researcher by the Australian Academy of Health and Medical Sciences (2022).
Dr Jiayan Liao is a dedicated researcher specialising in the field of nanotechnology, nanomedicine, biomedical engineering, and their applications in medical diagnostics. Dr Liao’s research focuses on developing innovative diagnostic tools for early cancer detection, leveraging photonics, fluorescent nanoprobes, and artificial intelligence for precise detection of single-molecule biomarkers in diseases and cancers. Dr Liao is contributing to the advancement of diagnostic methodologies and technologies, aiming for non-invasive, early detection methods to improve patient outcomes.
Professor Anthony Don is Professor of Medical Biochemistry in the School of Medical Sciences at the University of Sydney. His team develops and applies advanced mass spectrometry methods to investigate how alterations to brain lipid metabolism with ageing lead to dementia, develop neuroprotective therapeutics, and discover new biomarkers for demyelinating diseases. His research has uncovered deficits in lipid metabolism that destabilise myelin in the course of normal ageing and early in Alzheimer’s disease pathogenesis. He also developed and coordinates the popular masters-level unit of study, Advances in Disease Diagnosis and Treatment.
Dr Romain Ragonnet is a Senior Research Fellow in the Epidemiological Modelling Unit at Monash University. Dr Ragonnet specialises in the mathematical modelling of tuberculosis (TB) and COVID-19, and his notable contributions include the first-ever quantification of TB mortality and self-recovery rates. Dr Ragonnet has advised various governments of lower-middle-income countries in the Asia-Pacific region to assist the local control of TB and COVID-19. He also initiated and led multiple cross-disciplinary collaborations, creating a strong network of world-leading experts that spans mathematics, medical ethics, biostatistics, economics, and clinical trials.